INTELLIMMU
DEAD

Serial Number

97573907

Owner

Intellimmu Biopharma Inc.

Attorney

Yue (Robert) Xu

Filing Date

Aug 31, 2022

Add to watchlist:

No watchlists yet
View on USPTO

INTELLIMMU Trademark

Serial Number: 97573907

INTELLIMMU is a trademark filed by Intellimmu Biopharma Inc. on August 31, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Intellimmu Biopharma Inc.

Fifth Floor, Zephyr House,
P.O.Box 31493,KY1 1206 31493 , KY

Entity Type: 99

Trademark Details

Filing Date

August 31, 2022

Registration Date

Not Registered

Goods & Services

Diagnostic preparations for medical purposes; Depuratives for the body; Veterinary preparations for treatment of intestinal bacteria; Diagnostic preparations for medical or veterinary purposes; Pesticides; First aid kits; Dental abrasives; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the central nervous system; Medicines for alleviating constipation; Pharmaceutical preparations for treating diabetes; pharmaceutical preparations used for the treatment of reproductive system disorders; Aspirin; Medical preparations, namely, foot, hand and skin creams for diabetics; Medicines for human purposes, for treatment of hyperuricemia; Medical hemostatic paste; Medicines for human purposes, for the treatment of hepatitis B, Aids, retinal pigment degeneration and glioma; Medicines for human purposes, for the treatment of frequent micturition, urgency of urination and urge urinary incontinence; Pharmaceutical preparations for use in the treatment of muscle spasms, pain and related musculoskeletal disorders; Medicines for human purposes, for the treatment of gastric ulcer, duodenal ulcer and chronic gastritis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical products for the treatment of cancer; Medicines for intestinal disorders; Pharmaceutical preparations for use in urology; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of eye diseases and conditions; all the aforementioned goods exclude dietary supplements

Technological research in the field of medicine; Research and development of new products for others; Product quality evaluation; Chemical analysis; Scientific research in the nature of conducting clinical trials for others; Scientific research and development; Consulting services in the field of pharmaceutical research and development; Scientific research for medical purposes in the area of cancerous diseases; Scientific investigations for medical purposes; Biotechnology research; Pharmaceutical drug development services; Biomedical research services; Research and development services in the field of antibodies; Pharmaceutical research services; Development of pharmaceutical preparations and medicines; Biological research; Medical research; Stem cell research services; all the aforementioned services are not in relation to dietary supplements

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Feb 8, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Feb 8, 2024 ABN2
ASSIGNED TO EXAMINER
Feb 8, 2024 DOCK
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 24, 2023 GNFN
FINAL REFUSAL E-MAILED
Oct 24, 2023 GNFR
FINAL REFUSAL WRITTEN
Oct 24, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 15, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 14, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 14, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 26, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 26, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 26, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 15, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 20, 2022 NWOS
NEW APPLICATION ENTERED
Sep 3, 2022 NWAP